Michele Farmer, Chief Accounting Officer at Pacific Biosciences of California, Inc., executed sales of company common stock on February 17 and 18, 2026, disposing of a combined 50,167 shares for approximately $79,855 in total proceeds.
On February 17, Farmer sold 35,215 shares at a weighted average price of $1.576 per share, with individual trade prices spanning from $1.51 to $1.68. The following day, February 18, she sold an additional 14,952 shares at a weighted average of $1.629 per share, with prices ranging from $1.55 to $1.70.
The company’s stock is trading at $1.68 at the time of reporting, reflecting a 1.75% decline over the past week, while the shares have appreciated 32% over the last six months. InvestingPro analysis cited in the company profile indicates that Pacific Biosciences appears undervalued at current levels based on Fair Value calculations.
The disposition of these shares was undertaken to satisfy tax withholding requirements associated with the vesting of restricted stock units. After completing these transactions, Farmer directly holds 219,092 shares of Pacific Biosciences.
Separately, Pacific Biosciences reported its fourth-quarter 2025 financial results, delivering a narrower-than-expected loss per share and revenue that exceeded forecasts. The company posted a loss per share of $0.12 for the quarter, an outcome that was more favorable than the anticipated loss of $0.15, representing a 20% positive surprise relative to expectations. Quarterly revenue reached $44.6 million, surpassing the forecasted $42.27 million and coming in 5.51% above projections.
These results demonstrate the company outperformed market predictions on both the earnings-per-share and revenue fronts for the period. The stock experienced a modest uptick in aftermarket trading following the release of the quarterly figures. The company’s earnings and revenue metrics remain central to investor attention, and market participants are likely to continue watching Pacific Biosciences’ financial performance and strategic developments closely.
Note: The insider sales described above were reported as transactions to cover tax withholding obligations arising from vested restricted stock units. No additional motives or future actions were stated in the company filings referenced in the transactions.